THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES
Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient.
1 . A method for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a disease characterized by the production of effector cells, the method comprising monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.
2 . A method of treating a disease characterized by the production of effector cells, the method comprising;
i) analysing effector cell and/or regulator cell cycling by monitoring a patient suffering from the disease for fluctuations in at least one of:
a) number and/or activity of regulator cells,
b) number and/or activity of effector cells,
c) a molecule associated with the disease, and/or
d) an immune system marker, and
ii) exposing the patient to an agent to treat the disease.
3 . The method of claim 2 , wherein the agent is administered when, or just before, effector cells begin clonally expanding.
4 . The method according to any one of claims 1 to 3 , wherein the immune system marker is an acute phase inflammatory marker.
5 . The method of claim 4 , wherein the acute phase inflammatory marker is selected from the group consisting of serum amyloid A, serum amyloid P and c-reactive protein.
6 . The method according to any one of claims 2 to 5 , wherein the agent is administered between when the levels of an acute phase inflammatory marker have reached their lowest point and before the marker peaks in the next cycle.
7 . The method according to any one of claims 1 to 6 , wherein the disease characterized by the production of effector cells is an autoimmune disease or transplantation rejection.
8 . The method according to any one of claims 1 to 7 , wherein the immune system marker reflects the number and/or activity of regulator cells, and/or the number and/or activity of effector cells.
9 . The method according to any one of claims 1 to 8 , wherein the effector cells are CD8+CD4− T cells.
10 . The method of claim 9 , wherein the agent is administered between when CD8+CD4− T cells numbers are at their lowest point and before CD8+CD4− T cells numbers peak in the next cycle.
11 . The method according to any one of claims 1 to 10 , wherein the regulator cells are CD4+CD8− T cells.
12 . The method of claim 11 , wherein the agent is administered approximately when, or just before, CD4+CD8− T cell numbers have peaked.
13 . The method according to any one of claims 1 to 12 , wherein the patient is monitored for a period of at least 7 days.
14 . The method according to any one of claims 1 to 13 , the patient is monitored at least about every 3 days.
15 . The method according to any one of claims 1 to 14 , wherein the agent inhibits the production of, limits the function of, and/or destroys, effector cells.
16 . The method of claim 15 , wherein the agent is selected from the group consisting of anti-proliferative drugs, anti-metabolic drugs, radiation, dsRNA and antibodies which inhibit the production, limit the function of and/or activity of effector cells.
17 . The method of claim 16 , wherein the anti-proliferative drug is selected from the group consisting of: taxol, vincristine, vinblastine and anhydro vinblastine.
18 . The method of claim 16 , wherein the antibody is anti-CD8+ antibody.
19 . The method according to any one of claims 1 to 18 , wherein the patient is a human.
20 . A method for analysing effector cell and/or regulator cell cycling to diagnose a disease characterized by the production of effector cells, the method comprising monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker, wherein cycling of any one of a) to d) indicates the disease may be present.
21 . Use of an assay which detects an immune system marker for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a disease characterized by the production of effector cells.
22 . The use of claim 21 , wherein the marker is an acute phase inflammatory marker.
23 . The use of claim 22 , wherein the acute phase inflammatory marker is selected from the group consisting of serum amyloid A, serum amyloid P and c-reactive protein.
24 . Use of an assay which detects effector cell numbers and/or activity for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a disease characterized by the production of effector cells.
25 . The use of claim 24 , wherein the assay detects the number of CD8+CD4− T cells.
26 . Use of an assay which detects regulator cell numbers and/or activity for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a disease characterized by the production of effector cells.
27 . The use of claim 26 , wherein the assay detects the number of CD4+CD8− T cells.
28 . Use of an assay which detects a molecule associated with a disease characterized by the production of effector cells for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to treat the disease.
29 . Use of an agent for the manufacture of a medicament for administering to a patient suffering from a disease characterized by the production of effector cells, wherein the agent inhibits the production of, limits the function of, and/or destroys, effector cells.
30 . A kit when used for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a disease characterized by the production of effector cells, the kit comprising at least one reagent for monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.
31 . A method for analysing effector cell and/or regulator cell cycling to determine when an agent should be administered to a patient suffering from a degenerative disease, the method comprising monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.
32 . A method of treating a degenerative disease, the method comprising;
i) analysing effector cell and/or regulator cell cycling by monitoring a patient suffering from the disease for fluctuations in at least one of:
a) number and/or activity of regulator cells,
b) number and/or activity of effector cells,
c) a molecule associated with the disease, and/or
d) an immune system marker, and
ii) exposing the patient to an agent to treat the disease,
wherein the timing of administration of the agent is selected such that the activity of effector cells is not significantly reduced.
33 . The method of claim 31 or claim 32 , wherein the degenerative disease is selected from: Alzheimer's disease, Parkinson's disease, Huntington's disease, Lou Gehrig's disease and a prion related disease.
34 . The method of claim 33 , wherein the prion related disease is Creutzfeld-Jacob disease.
35 . The method according to any one of claims 31 to 34 , wherein the immune system marker reflects the number and/or activity of regulator cells, and/or the number and/or activity of effector cells.
36 . The method according to any one of claims 31 to 35 , wherein the immune system marker is an acute phase inflammatory marker.
37 . The method of claim 36 , wherein the acute phase inflammatory marker is selected from the group consisting of: serum amyloid A, serum amyloid P and c-reactive protein.
38 . The method according to any one of claims 32 to 37 , wherein the agent is administered between when the levels of an acute phase inflammatory marker have peaked and before the marker begins to rise in the next cycle.
39 . The method according to any one of claims 31 to 38 , wherein the regulator cells are CD4+CD8− T cells.
40 . The method according to any one of claims 32 to 39 , wherein the agent is administered between when CD4+CD8− T cells numbers are at their lowest point and before CD4+CD8− T cells numbers peak in the next cycle
41 . The method according to any one of claims 31 to 40 , wherein the effector cells are CD8+CD4− T cells.
42 . The method according to any one of claims 32 to 41 , wherein the agent is administered approximately when, or just before, CD8+CD4− T cell numbers have peaked.
43 . The method according to any one of claims 31 to 42 , wherein the patient is monitored for a period of at least 7 days.
44 . The method according to any one of claims 31 to 43 , the patient is monitored at least about every 3 days.
45 . The method according to any one of claims 31 to 44 , wherein the agent inhibits the production of, limits the function of, and/or destroys, regulator cells.
46 . The method of claim 45 , wherein the agent is selected from the group consisting of anti-proliferative drugs, anti-metabolic drugs, radiation, dsRNA and antibodies which inhibit the production and/or activity of regulator cells.
47 . The method of claim 46 , wherein the anti-proliferative drug is selected from the group consisting of: taxol, vincristine, vinblastine and anhydro vinblastine.
48 . The method of claim 46 , wherein the antibody is selected from the group consisting of: anti-CD4+, anti-CTLA-4 (cytotoxic lymphocyte-associated antigen-4), anti-GITR (glucocorticoid-induced tumour necrosis factor receptor), anti-CD28 and anti-CD25.
49 . The method according to any one of claims 31 to 48 , wherein the patient is a human.
50 . A method for analysing effector cell and/or regulator cell cycling to diagnose a degenerative disease, the method comprising monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker, wherein cycling of any one of a) to d) indicates the disease may be present.
51 . A method for analysing effector cell and/or regulator cell cycling to determine when a vaccine should be administered to a patient suffering from a degenerative disease, the method comprising monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.
52 . A method of treating a degenerative disease, the method comprising;
i) analysing effector cell and/or regulator cell cycling by monitoring a patient suffering from the disease for fluctuations in at least one of:
a) number and/or activity of regulator cells,
b) number and/or activity of effector cells,
c) a molecule associated with the disease, and/or
d) an immune system marker, and
ii) exposing the patient to an vaccine to treat the disease,
wherein the timing of administration of the vaccine is selected such that the activity of effector cells is not significantly reduced.
53 . The method of claim 52 , wherein the vaccine is administered about when the levels of effector cells are increasing.
54 . The method of claim 52 , wherein the vaccine is administered about when the levels of a molecule associated with the disease begin to decrease.
55 . The method of claim 52 , wherein the vaccine is administered about when the levels of an acute phase inflammatory marker begin to increase.
56 . Use of an assay which detects an immune system marker for analysing effector cell and/or regulator cell cycling to determine when an agent or vaccine should be administered to a patient suffering from a degenerative disease.
57 . The use of claim 56 , wherein the marker is an acute phase inflammatory marker.
58 . The use of claim 57 , wherein the acute phase inflammatory marker is selected from the group consisting of serum amyloid A, serum amyloid P and c-reactive protein.
59 . Use of an assay which detects effector cell numbers and/or activity for analysing effector cell and/or regulator cell cycling to determine when an agent or vaccine should be administered to a patient suffering from a degenerative disease.
60 . The use of claim 59 , wherein the assay detects the number of CD8+CD4− T cells.
61 . Use of an assay which detects regulator cell numbers and/or activity for analysing effector cell and/or regulator cell cycling to determine when an agent or vaccine should be administered to a patient suffering from a degenerative disease.
62 . The use of claim 61 , wherein the assay detects the number of CD4+CD8− T cells.
63 . Use of an assay which detects a molecule associated with a degenerative disease for analysing effector cell and/or regulator cell cycling to determine when an agent or vaccine should be administered to treat the disease.
64 . Use of an agent for the manufacture of a medicament for administering to a patient suffering from a degenerative disease, wherein the agent will be administered at a time selected such that the activity of effector cells is not significantly reduced.
65 . The use according to any one of claims 56 to 64 , wherein the agent inhibits the production of, limits the function of, and/or destroys, regulator cells.
66 . A kit when used for analysing effector cell and/or regulator cell cycling to determine when an agent or vaccine should be administered to a patient suffering from a degenerative disease, the kit comprising at least one reagent for monitoring the patient, or samples obtained therefrom, for fluctuations in at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.